Unicycive Therapeutics (UNCY) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 36.2% versus a loss of 13.1%. Over five years, VTVT leads with a -47.0% price change compared with -84.9% for UNCY. vTv Therapeutics is the larger company by market cap ($123.3 million vs $112.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UNCY | VTVT |
|---|---|---|
| Share price | $4.11 | $31.18 |
| Market cap | $112.59M | $123.28M |
| 1-day change | +0.98% | +3.66% |
| YTD return | -28.77% | -22.03% |
| 1-year return | -13.11% | +36.22% |
| 5-year return | -84.91% | -46.97% |
| Forward P/E | 2.44 | — |
| EPS (TTM) | $-1.72 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.74 | $44.00 |
| 52-week low | $3.93 | $19.50 |
| Distance from 52-week high | -52.97% | -29.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +591.00% | +75.47% |
| Average volume | 834.69K | 68.34K |
| Shares outstanding | 27.39M | 3.95M |
| Employees | 21 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed UNCY by 49.3 percentage points over the past year.
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
UNCY vs VTVT FAQ
Which is bigger, Unicycive Therapeutics or vTv Therapeutics?
vTv Therapeutics (VTVT) is larger, with a market capitalization of $123.28M compared with $112.59M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, UNCY or VTVT?
VTVT returned +36.22% over the past 12 months, compared with -13.11% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are Unicycive Therapeutics and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.